Navigation Links
EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
Date:8/19/2010

that its securities will be subject to delisting from the NASDAQ Capital Market. At that time, the Company will be permitted to appeal NASDAQ's determination to a Listing Qualifications Panel.

The Company intends to actively monitor its MVLS and alternative continued listing requirements to regain compliance with NASDAQ listing standards. The Company may seek to raise additional capital in conjunction with clinical developments over the course of the remaining year to increase stockholders' equity.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the N
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... , Dec. 23, 2014  Endo Pharmaceuticals Inc., ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, Inc. ... have submitted a New Drug Application (NDA) for Buprenorphine ... Administration (FDA).  Buprenorphine HCl Buccal Film is under development ... daily, around-the-clock, long-term opioid treatment and for which alternative ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2
... TAXUS(R) Stent shows no additional very late stent ... 4 ,Boston Scientific Corporation (NYSE: BSX ) ... II clinical trial, demonstrating continued,long-term safety and efficacy ... the TAXUS stent showed no additional stent,thrombosis between ...
... investigators at the,European Society of Cardiology Congress 2007 (ESC ... continued to,provide clinical benefits compared to a bare metal ... follow-up with no differences in safety. At five-year ... the,study continued to be significantly less likely than the ...
Cached Medicine Technology:Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 2Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 3Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
(Date:12/26/2014)... The Biofeedback Federation of Europe annual meeting is ... Italy and is hosted by the Salesian Pontifical University. ... wide variety of topics such as ADHD, anxiety, headaches ... athletes. The scientific program will feature the latest in ... clients to see what is going on in their ...
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... December 26, 2014 This is a ... the global Sterilizers industry with a focus on the ... market status of the Sterilizers manufacturers and is a ... individuals interested in the industry. This report provides a ... and manufacturing technology. In this part, the report presents ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3
... Toronto Stock Exchange Symbol: CYT, MONTREAL, Nov. ... global leader in cryotherapy products to treat cardiac,arrhythmias, ... of,CryoCath, will present at both the Piper Jaffray ... on Healthcare Conference. The Piper Jaffray,Conference presentation will ...
... Trigger Milestone Payments Totaling $1 Million to ... ... PCOP ), an innovator in the discovery and development of ... compounds for advancement in its alliance with GlaxoSmithKline (NYSE:,GSK), through its ...
... movie is a,psychological thriller that tells the story of a ... but paralyzed,during heart surgery., It has been 30 years ... ,Coma, is the gripping story of patients,who check into a ... "Five years after the book and movie, I still ...
... of Hematology ... (ASH) Annual Meeting, SEATTLE, Nov. ... announced it intends to utilize the,results of the phase III first-line ... submission to the United States Food,and Drug Administration (FDA) for potential ...
... Today at 10:30 CET, AMSTERDAM, November 27 ... the field of human gene therapy,today announced it ... the,development of AAV-mediated insulin-like growth factor I (IGF-I) ... CET today, the company,s,management will hold a conference ...
... is a close relationship between infection outbreaks on teeth and ... of hair loss which has an unknown origin. Alopecia areata ... on the body. The disease occurs in males and females ... out 1000 people. , Research by professors Jos Antonio Gil ...
Cached Medicine News:Health News:CryoCath to present at Piper Jaffray and BMO Healthcare conferences 2Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 2Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 3Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 4Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 5Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 2Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 3Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 2Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 3Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 4Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 5Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 6Health News:Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008 2Health News:Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008 3Health News:Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008 4Health News:Infection outbreaks on teeth can cause 'alopecia areata' or localized hair loss 2
... Releasing the power of clinical information. ... newest generation of clinical connectivity solutions that ... provide effective, high-quality patient care. You will ... be able to share it with your ...
... tool for Clinical Professionals and Researchers., ,S/5 ... easy and efficient way to collect data from ... to days at selectable time intervals. With S/5 ... from the monitor via an interface cable or ...
... Flexible monitoring for intermediate care., ,The ... GE Healthcare Datex-Ohmeda S/5 product line., ,The ... you the power to grow. The new Patient ... hemodynamic measurements up to 12-lead ECG, NIBP, ...
... ,The Datex-Ohmeda S/5 Light Monitor is a ... and critical care areas, in emergency or medium-care ... part of the Datex-Ohmeda S/5 family, the S/5 ... and design shared by all S/5 monitoring products ...
Medicine Products: